Recent Trends of Prenatal Screening for Down Syndrome.
- Author:
Moon Young KIM
1
Author Information
1. Department of Obstetrics and Gynecology, Samsung Cheil Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. mykimdr@yahoo.co.kr
- Publication Type:Review
- Keywords:
Down syndrome;
Screening tests;
Serum markers;
Nuchal translucency
- MeSH:
Biomarkers;
Chorionic Gonadotropin;
Down Syndrome*;
Female;
Humans;
Mass Screening;
Maternal Age;
Nuchal Translucency Measurement;
Pregnancy-Associated Plasma Protein-A;
Prenatal Diagnosis*
- From:Korean Journal of Obstetrics and Gynecology
2006;49(1):5-17
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Prenatal diagnosis of Down syndrome requires an invasive test in women considered to be at high risk after screening. At present, there are variable screening tests. For a 5% false-positive rate, the sensitivities are approximately 20-30% for maternal age alone, 60-70% for maternal age and second-trimester maternal serum markers, 85% for maternal age with fetal nuchal translucency and maternal serum free beta-human chorionic gonadotropin (beta-hCG) and pregnancy-associated plasma protein-A (PAPP-A) at 11-14 weeks, and 94% for maternal age with fetal nuchal translucency and maternal serum free beta-human chorionic gonadotropin (beta-hCG) and pregnancy-associated plasma protein-A (PAPP-A) at 11-14 weeks following second-trimester maternal serum markers. This article examines the studies of screening for Down syndrome and summarizes the results from major studies reporting on the implementation of this method.
